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The development of new drugs and devices is expensive
with long timelines and high rate of failure. The director
of NIH is concerned with these issues and has made
reengineering the translational sciences a top priority [1].
One outcome of the planning has been the creation of a
new NIH National Center for Advancing Translational
Sciences (NCATS) [2]. NCATS has three major goals:
reengineering translational sciences, creating a network
of clinical and translational science awardees (CTSAs) at
60 academic institutions in the US and supporting
research on rare diseases and therapeutics. Recent novel
approaches to technology development under NCATS
leadership include designing new “organ chips” and use
of induced pluripotent stem cells (iPS cells) to screen for
drug toxicity. Another project is the 1000 genomes pro-
ject which estimated that human genomes typically con-
tain about 100 genuine loss of function variants with
about 20 genes completely inactivated but without
obvious disease consequence. In some cases the loss of
function variants are associated but with protection from
disease thereby providing new targets for drug discovery
[3]. Another effort to reengineer drug discovery is a drug
repurposing project that has resulted in partnerships with
8 pharmaceutical companies who recently announced 58
compounds available for repurposing studies [4]. The
Office of Rare Diseases Research has moved into NCATS
and is working to establish partnerships throughout the
world for the study of rare diseases. The Office of Rare
Diseases Research continues to work on the development
of novel treatment strategies. The NIH Clinical Center,
the largest hospital in the world totally dedicated to clini-
cal research, will work closely with NCATS. A new vision
for the NIH Clinical Center will be “to open its doors” to
outside investigators through new partnerships between
extramural scientists and investigators in the NIH intra-
mural program. These partnerships will include access to
the special technical resources at the Clinical Center,
access to the clinical research training programs including
the NIH curriculum for clinical research training, courses
designed to demystify medicine for PhDs, as well as a sab-
batical in clinical research management. In addition, the
Clinical Center will make available new tools it has devel-
oped for protocol management and information technol-
ogy (see http://www.cc.nih.gov/ for review of the Clinical
Center programs). The many approaches NIH is imple-
menting to improve translational research will be moni-
tored closely for success.
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